The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.
Jan Stoehlmacher-Williams
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Other Remuneration - Amgen
Cristian Villanueva
No relevant relationships to disclose
Paolo Foa
No relevant relationships to disclose
Sylvie Rottey
No relevant relationships to disclose
Eric Winquist
Consultant or Advisory Role - Amgen (U)
Lisa F. Licitra
No relevant relationships to disclose
Irina Davidenko
No relevant relationships to disclose
Krzysztof A. Skladowski
Consultant or Advisory Role - Amgen
Makoto Tahara
Consultant or Advisory Role - Merck Serono
Honoraria - Aventis; Taiho Pharmaceutical; Takeda
Research Funding - Eisai; Yakult Honsha
Sandrine J. Faivre
Honoraria - Amgen
Research Funding - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Zhiying Pan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Bruce A. Bach
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jan Baptist Vermorken
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Merck Serono
Honoraria - Amgen; Boehringer Ingelheim; Merck Serono